Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.
Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.
The objective of the HERO trial was to compare the oral, once-daily gonadotropin-releasing hormone agonist relugolix (Relumina) with 3-month leuprolide (Lupron) in patients with advanced prostate cancer, says Shore. The primary end point of the study was testosterone (T)-suppression through 48 weeks. Results showed noninferiority, as well as superiority with regard to T-suppression with relugolix over leuprolide acetate.
The patients included in this trial had prostate-specific antigen (PSA) or biochemical relapse; relapsed after surgery, radiation, or both; or had newly diagnosed metastatic disease or high-risk localized disease. The demographics were well balanced in terms of age, race, and geographic region, as well as clinical characteristics regarding their baseline PSAs, as well as their testosterone levels, concludes Shore.